DoD Autism, Clinical Trial Award
ID: 353176Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353176
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering a grant opportunity titled "DoD Autism, Clinical Trial Award" aimed at advancing research in Autism Spectrum Disorders (ASD). This grant supports the rapid implementation of clinical trials that can significantly impact the treatment or management of ASD, with a strong encouragement for applications to address specific areas of interest outlined for FY24. The total estimated funding for this program is $6.56 million, with the expectation of awarding two grants, and applications are due by August 15, 2024, following a pre-application process due by May 16, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    FY24.pdf
    The Department of Defense has issued a Clinical Trial Award for the Fiscal Year 2024 under the Autism Research Program (ARP) specifically targeting early-career investigators. Eligible principal investigators (PIs) must meet specific criteria by the application deadline of August 15, 2024, including dedicating at least 50% of their efforts to the proposed clinical research. Additionally, candidates should be within seven years of obtaining a terminal degree (excluding time spent in residency or family medical leave) and have completed a postdoctoral training position by the deadline. The document requires the PI to certify their eligibility and provides sections for both PI and an official from their organization to validate the information. This initiative aims to foster research addressing autism while ensuring that emerging researchers are actively engaged in clinical investigations.
    HT942524ARPCTA_GG.pdf
    The Department of Defense (DOD) has announced the Fiscal Year 2024 Autism Clinical Trial Award under the Autism Research Program (ARP), with funding aimed at advancing research in Autism Spectrum Disorders (ASD). The total funding allocated for FY24 is $15 million, specifically to support impactful clinical trials relevant to service members, veterans, and the general public. The application process is structured in two steps: a pre-application due by May 16, 2024, followed by full applications by August 15, 2024, contingent on invitation following pre-screening. Research proposals should align with specified areas of interest, including community-led interventions, pharmacological treatments, and mental health issues in autistic populations. Researchers are encouraged to establish collaborations to enhance the research's impact. The award supports trials with up to $1.9 million in direct costs, allowing higher amounts for collaborations involving early-career investigators. This initiative reflects the government’s commitment to improving outcomes for individuals with ASD, signifying a critical funding opportunity for clinical research in this field. Applications must adhere to stringent guidelines outlined in the funding announcement to be eligible for review and funding.
    Similar Opportunities
    DOD USAMRDC FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural Medical Research
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Development Command (USAMRDC), has announced the FY23-FY27 Broad Agency Announcement (BAA) for Extramural Medical Research, which is open for submissions from October 1, 2022, to September 30, 2027. This opportunity invites innovative research proposals that address critical military medical challenges, particularly in the areas of Military Infectious Diseases, Combat Casualty Care, and Military Operational Medicine, with a focus on enhancing medical practices for both military personnel and civilians. The BAA emphasizes the importance of collaboration with Department of Defense and Department of Veterans Affairs resources and requires adherence to strict submission guidelines via Grants.gov and the electronic Biomedical Research Application Portal (eBRAP). Interested applicants can submit pre-proposals at any time during the five-year period, with full proposals invited based on initial submissions, and should direct inquiries to the CDMRP Help Desk at help@eBRAP.org.
    Tactical Behaviors for Autonomous Maneuver
    Dept of the Army -- Materiel Command
    The Department of the Army's Materiel Command is offering a funding opportunity through the Tactical Behaviors for Autonomous Maneuver Collaborative Research Program (TBAM-CRP) aimed at enhancing the capabilities of robotic and autonomous systems (RAS) for military operations in complex environments. This program seeks proposals that develop coordinated and adaptive behaviors for small groups of autonomous agents, focusing on innovative maneuver tactics and strategies to operate effectively in multi-domain operations against peer adversaries. The TBAM-CRP is critical for advancing military capabilities, leveraging new technologies in robotics and autonomous systems to improve situational awareness and operational effectiveness on the battlefield. Interested applicants, including institutions of higher education and for-profit organizations, are invited to submit proposals by April 24, 2024, with funding amounts ranging from $100,000 to $2.3 million available per award. For further inquiries, applicants can contact Christopher D. Justice at usarmy.adelphi.devcom-arl.mbx.tbam-crp-questions@army.mil.
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    Department of Defense HIV/AIDS Prevention Program
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering a federal grant opportunity titled the Department of Defense HIV/AIDS Prevention Program (DHAPP). This program aims to save lives and prevent HIV infections by supporting the development of interventions and programs within military health systems, particularly in foreign countries, to achieve HIV/AIDS epidemic control. The DHAPP focuses on enhancing military capacity for ownership and behavioral change, aligning with national strategies, and ensuring sustainable HIV prevention and treatment services. Interested applicants can reach out to Ebony Simmons at ebony.s.simmons.civ@health.mil or by phone at 301-619-2105 for further information. The application deadline is September 18, 2027, with an expected seven awards to be made under this cooperative agreement, which does not require cost sharing or matching.
    NFRP Outreach and Invitation for Response
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), is forecasting an opportunity for a Research-based Other Transactions Agreement (rOTA) under the Neurofibromatosis Research Program (NFRP). This initiative aims to accelerate the clinical translation of basic research related to neurofibromatosis (NF) by conducting collaborative Phase I and II clinical trials focused on promising therapeutic agents for NF1, NF2, and schwannomatosis. Historically, this requirement has been addressed through assistance agreements, and the government is now seeking feedback on this proposed approach, emphasizing the need for cost-sharing arrangements and access to patient populations. Interested parties can direct inquiries to Jason D. Kuhns at jason.d.kuhns.civ@mail.mil, with the opportunity being part of the FY21 portfolio and requiring a demonstrated history of collaborative research among participants.
    Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a funding opportunity for clinical trials aimed at addressing unmet needs in rare neurodegenerative diseases through the Notice of Funding Opportunity (NOFO) RFA-FD-25-001. This initiative, mandated by the ACT for ALS Act, seeks to support trials that evaluate the efficacy and safety of products for new indications or changes in labeling, with the goal of increasing the number of approved treatments for these conditions affecting fewer than 200,000 individuals in the U.S. Eligible applicants include various organizations such as higher education institutions and non-profits, with funding amounts capped at $650,000 for standard applications and up to $900,000 for innovative approaches. Interested parties should note that applications will be accepted starting August 23, 2024, with letters of intent and full applications due by October 22, 2024. For further inquiries, applicants can contact Terrin Brown at terrin.brown@fda.hhs.gov.
    Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a federal grant opportunity titled "Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required." This grant aims to fund clinical trials that evaluate the efficacy and safety of products intended to address unmet needs in rare neurodegenerative diseases affecting both children and adults, thereby increasing the number of approved treatments in this critical area. The initiative is part of the FDA's broader effort to enhance drug development for rare diseases, which is vital for improving health outcomes in affected populations. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610 for more information, with funding amounts ranging from $650,000 to $900,000 for the fiscal year 2025.
    Fiscal Year (FY) 2026 Department of Defense Multidisciplinary Research Program of the University Research Initiative (MURI) Department of Defense Army
    Dept of the Army -- Materiel Command
    The Department of the Army's Materiel Command is offering a funding opportunity through the Fiscal Year 2026 Multidisciplinary Research Program of the University Research Initiative (MURI), aimed at fostering innovative research with military applications. This program invites proposals exclusively from U.S. institutions of higher education, including universities with degree-granting programs in science and engineering, to conduct high-risk basic research that addresses significant scientific challenges. With an estimated total program funding of $170 million over five years, the MURI program will support annual grants of up to $1.5 million, with proposals due by September 5, 2025, and optional white papers due by May 2, 2025. Interested applicants can reach out to Dr. Sue Kase at usarmy.rtp.devcom-arl.mbx.aro-muri@army.mil for further information.
    Notice of Intent to Publish a Notice of Funding Opportunity for Biomarkers of Cognitive Decline and Dementias of Aging in Individuals within the Autism Spectrum (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at advancing research on biomarkers of cognitive decline and dementias in individuals on the Autism Spectrum. This initiative seeks to conduct observational studies utilizing deep phenotyping techniques, including neuroimaging and molecular approaches, to identify and characterize neurodegeneration biomarkers in this population, as well as to evaluate existing dementia biomarkers in the context of Autism Spectrum Disorders (ASD). The total estimated funding for this program is $5 million, with the NOFO expected to be published in December 2024 and applications due by February 2025, leading to awards anticipated by September 2025. Interested applicants are encouraged to prepare collaborative proposals in advance of the official announcement.
    Drug Development Tools Research Grants (U01) Clinical Trials Optional
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering Drug Development Tools Research Grants (U01) to support research aimed at advancing drug development tools (DDTs) that have an accepted or reviewable Letter of Intent within the FDA's qualification program. These grants are intended for developers working towards their qualification plan or full qualification package, focusing on tools that can enhance public health by optimizing the drug development process, such as biomarkers or animal models. The funding opportunity provides up to $500,000 for a maximum two-year period, with applications due by May 13, 2024, and May 13, 2025. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov for further information and are encouraged to review the detailed announcement available at https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-030.html.